B-Cell Lymphomas (non-Hodgkin)

C82-C85, C88, C91WHO Vol. 11 (2024)

Haematolymphoid System

Prognosis

This section is being prepared by our editorial process.

🔬 Histological Types

📚 Latest Research

2026-09-10

Cytokine concentrations in pediatric primary mediastinal large B cell lymphoma correlate with disease extent and outcome.

Nipper M, et al

A population-based study of 62 pediatric patients with primary mediastinal large B-cell lymphoma (PMBCL) identified pretreatment plasma cytokine profiles that distinguish tumor burden from prognosis, with IL-6 showing the strongest link to outcome — a hazard ratio of 6.8 (95% CI, 1.5–30.9) for inferior event-free survival. CCL17 levels were dramatically elevated in PMBCL patients compared to 26 age-matched controls (median 1695 pg/ml vs. 81 pg/ml; p<0.0001), and CCL17, CXCL9, and CXCL10 correlated significantly with mediastinal tumor volume and lactate dehydrogenase activity, though not with survival. In a uniformly treated subgroup of 50 patients receiving dose-adjusted EPOCH with rituximab, elevated IL-6, IL-10, IL-17A, and IL-22 each predicted inferior event-free survival, establishing a panel of novel biomarkers that may guide risk stratification in this lymphoma subtype currently lacking established prognostic markers.

Blood advances

Source →

2026-09-09

Barriers to Patient Referral and Completion of CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma.

Shadman M, et al

A multistakeholder panel convened on October 8, 2025, identified critical barriers preventing medically eligible patients with relapsed or refractory large B-cell lymphoma in the United States from receiving CAR T-cell therapy, a proven treatment for this hematologic malignancy. Key obstacles identified included limited patient awareness of CAR T-cell therapy, inadequate knowledge and application of eligibility criteria among clinicians, as well as logistical, financial, and health system process-related delays. The panel recommended expanding CAR T-cell therapy delivery to community treatment sites and relocating supportive resources — including financial counselors, social workers, and patient navigators — from specialized treatment centers to community oncology practices. These findings highlight a significant and actionable gap between patient eligibility and actual receipt of a potentially life-saving therapy.

Transplantation and cellular therapy

Source →

2026-09-09

Protocol and Cohort Profile of a Prospective Multicenter Lymphoma Cohort in South Korea.

Kang D, et al

A prospective multicenter lymphoma cohort established in South Korea has enrolled 2,370 patients — including 1,726 with B-cell non-Hodgkin lymphoma, 501 with T- or NK-cell non-Hodgkin lymphoma, and 143 with Hodgkin lymphoma — combining standardized clinical registry data with high-frequency patient-reported outcomes collected via a mobile web-based platform. Building on institutional registries founded in 2010 and a multicenter prospective expansion launched in April 2023, the cohort uses the PRO-CTCAE system to assess symptoms at seven predefined time points per chemotherapy cycle, capturing detailed longitudinal symptom trajectories in real-world patients. This infrastructure is designed to fill a critical gap in real-world oncology data by enabling patient-centered outcome monitoring and supporting future pragmatic clinical trials in lymphoma.

Journal of clinical epidemiology

Source →